A Risk Model for Surgical Site Infection in the Gastric Cancer Surgery Using Data of 790 Patients

2015 ◽  
Vol 32 (6) ◽  
pp. 472-479 ◽  
Author(s):  
Hideki Ushiku ◽  
Kei Hosoda ◽  
Keishi Yamashita ◽  
Natsuya Katada ◽  
Shiro Kikuchi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Surgical Site Infection ◽  
Risk Model ◽  
Cancer Surgery ◽  
Site Infection ◽  
Gastric Cancer Surgery ◽  
Using Data

scholarly journals The incidence and risk factors for surgical site infection in older adults after gastric cancer surgery

Medicine ◽  
2019 ◽  
Vol 98 (32) ◽  
pp. e16739
Author(s):  
Jung Ho Kim ◽  
Jinnam Kim ◽  
Woon Ji Lee ◽  
Hye Seong ◽  
Heun Choi ◽  
...  
Keyword(s):  
Risk Factors ◽  
Gastric Cancer ◽  
Older Adults ◽  
Surgical Site Infection ◽  
Cancer Surgery ◽  
Site Infection ◽  
Gastric Cancer Surgery

Relation between Sarcopenia and Surgical Site Infection in Patients Undergoing Gastric Cancer Surgery

2020 ◽  
Author(s):  
Tolga Olmez ◽  
Selcuk Gulmez ◽  
Erdal Karakose ◽  
Cem Batuhan Ofluoglu ◽  
Aziz Serkan Senger ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Surgical Site Infection ◽  
Cancer Surgery ◽  
Site Infection ◽  
Gastric Cancer Surgery

scholarly journals Effect of triclosan-coated sutures on surgical site infection after gastric cancer surgery via midline laparotomy

2014 ◽  
Vol 87 (6) ◽  
pp. 311 ◽  
Author(s):  
Kuk Hyun Jung ◽  
Seung Jong Oh ◽  
Kang Kook Choi ◽  
Su Mi Kim ◽  
Min Gew Choi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Surgical Site Infection ◽  
Cancer Surgery ◽  
Site Infection ◽  
Midline Laparotomy ◽  
Gastric Cancer Surgery

A randomized phase III trial to determine the efficacy of postoperative antimicrobial prophylaxis in gastric cancer surgery (OGSG0501)

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e15576-e15576
Author(s):  
K. Inoue ◽  
H. Imamura ◽  
Y. Kimura ◽  
K. Fujitani ◽  
Y. Miyake ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Surgical Site Infection ◽  
Infection Rate ◽  
Distal Gastrectomy ◽  
Antimicrobial Prophylaxis ◽  
Cancer Surgery ◽  
Phase Iii ◽  
Site Infection ◽  
Phase Iii Trial ◽  
Gastric Cancer Surgery

e15576 Background: In Japan, antimicrobial prophylaxis (AMP) is typically administered for 3 to 4 days postoperatively in gastric cancer surgery. This far exceeds the recommended 24h or less laid out by the Centers for Disease Control (CDC) guidelines for the prevention of surgical-site infections, after a clean-contaminated operation. Methods: A multicenter randomized phase III trial was designed to evaluate the effect of postoperative AMP in gastric cancer surgery. Patients (pts) were required to have histologically proven gastric cancer which was curable by distal gastrectomy, be classifiable as ASA 1 or 2, and have adequate organ function. Pts were randomized to: (A) perioperative AMP (cefazolin 1g, at <30min before incision, every 3h intraoperative supplements) plus postoperative AMP (cefazolin 1g, twice daily for 2 postoperative days) or (B) perioperative AMP alone. Pts were stratified by institution and ASA. The primary endpoint was the incidence of surgical site infection (SSI). With 171 pts per arm, this study had 80% power to demonstrate non-inferiority with 5% margin of peri-AMP alone and 0.05 1-sided alpha. Results: 355 patients were recruited (A: 179, B: 176) in 7 centers between June 2005 and December 2007. The surgical-site infection rate was 9.0 percent (16 of 178) for peri-/post AMP and 4.5 percent (8 of 176) for peri-AMP alone, with no significant differences (Fisher's exact test: P=0.14, RR=1.98 [95%CI, 0.89–4.44]), but showing a significant non-inferiority (P<0.001). The remote site infection rate was 3.4 percent (6 of 178) for peri-/post AMP and 5.1 percent (9 of 175) for peri-AMP alone, with no significant differences (P=0.44, RR=0.66 [95%CI, 0.25- 1.70]). Conclusions: This multicenter randomized phase III trial confirms that postoperative AMP is unnecessary in patients undergoing distal gastrectomy for gastric cancer. No significant financial relationships to disclose.

scholarly journals A Prospective Randomized Study to Assess the Optimal Duration of Intravenous Antimicrobial Prophylaxis in Elective Gastric Cancer Surgery

2012 ◽  
Vol 97 (2) ◽  
pp. 169-176 ◽  
Author(s):  
Norihiro Haga ◽  
Hideyuki Ishida ◽  
Toru Ishiguro ◽  
Kensuke Kumamoto ◽  
Keiichiro Ishibashi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Single Dose ◽  
Multiple Dose ◽  
Dose Group ◽  
Antimicrobial Prophylaxis ◽  
Randomized Study ◽  
Surgical Site Infections ◽  
Cancer Surgery ◽  
Site Infection ◽  
Gastric Cancer Surgery

Abstract The duration of antimicrobial prophylaxis in gastric cancer surgery is not yet established. This prospective randomized study was performed to confirm the noninferiority of single-dose versus multiple-dose antimicrobial prophylaxis in terms of the incidence of surgical-site infection in gastric cancer surgery. Three hundred twenty-five patients undergoing elective resection for gastric cancer were randomized to receive only single-dose cefazolin (1 g) during surgery (single-dose group) or an additional 5 doses every 12 hours postoperatively (multiple-dose group). The overall incidence of surgical-site infections was 9.1% in the single-dose group and 6.2% in the multiple-dose group [difference (95% confidence interval): −2.9% (−5.9%–0.0%)]. Multivariate logistic regression analysis identified blood loss, being overweight, and advanced age as significant independent risk factors for surgical-site infection. Single-dose antimicrobial prophylaxis seemed to be acceptable, and choosing multiple-dose prophylaxis may have little impact on the prevention of surgical-site infections in elective gastric cancer surgery.

Sign in / Sign up

Export Citation Format

Share Document